AI-assisted, human-published
09/18/2024 /M & A
NanoVation Therapeutics and Novo Nordisk Collaborate on Genetic Medicine Development
NanoVation Therapeutics partners with Novo Nordisk to develop genetic medicines targeting cardiometabolic and rare diseases. The collaboration involves leveraging NanoVation's long-circulating lipid nanoparticle (lcLNP™) technology for RNA delivery and Novo Nordisk's expertise in R&D and clinical translation.
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com